Biomarker in CKD Patients Could Help Gauge Dialysis Effectiveness

Serum FGF23 levels can help to determine the treatment effect of dialysis in patients with chronic kidney disease (CKD), according to a recent study.

In order to investigate the impact of serum FGF23 levels of blood pressure in patients with CKD, researchers conducted a study involving 128 patients divided into stages according to glomerular filtration rate. Enzyme-Linked ImmunoSorbent Assay was used to detect serum FGF23 levels in CKD patients and healthy controls, and 24-hour blood pressure monitoring was used to measure mean arterial pressure.
___________________________________________________________________________________________

RELATED CONTENT
CKD Risk Influenced by Quality of Care in Diabetes Patients
Are Anticoagulants Safe for Patients With Concomitant AF, CKD?
___________________________________________________________________________________________

Overall, the researchers observed that the serum FGF23 levels of CKD patients were significantly higher than in healthy controls. FGF23 levels were found to be positively correlated with mean arterial pressure and negatively correlated with glomerular filtration rate.

“Serum FGF23 level is positively correlated with mean arterial pressure and negatively correlated with glomerular filtration rate. So, FGF23 has an important clinical significance that can reflect blood pressure and treatment effect of dialysis of CKD patients,” the researchers concluded.

—Michael Potts

Reference:

Li JX, YGQ, Zhuang YZ. Impact of serum FGF23 levels on blood pressure of patients with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2018;22(3):721-725.